# Amani Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amani-therapeutics

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.amanitx.com/
- Total disclosed funding: $25M
- Latest round: Series A (Mar 23, 2026)
- Investors on record: 1

## About

Amani Therapeutics is a US-based biotech firm focused on developing innovative therapies for serious neuropsychiatric disorders, particularly targeting treatment-resistant schizophrenia with its lead product AM-01.Amani Therapeutics, founded in 2025 in New York, US, is dedicated to addressing neuropsychiatric disorders through the development of advanced therapies. The company achieved its most recent funding round, Series A, on March 23, 2026, raising a total of USD 25.00 mn from RTW Investments. This funding reflects strong investor interest and will be utilized to further clinical development of AM-01, its flagship therapy.Amani Therapeutics specializes in developing innovative therapies for serious neuropsychiatric disorders, focusing on its lead product, AM-01. This therapy is a fixed-dose combination of clozapine and a novel chemical entity designed to maximize efficacy for treatment-resistant schizophrenia while reducing the risk of severe neutropenia. The company aims to improve patient outcomes by facilitating effective treatment options for psychiatric illnesses and collaborates with healthcare providers and pharmacies to ensure access to its products.Amani Therapeutics has secured USD 25.00 mn in Series A funding to advance the development of AM-01. Revenue generation is expected through partnerships with healthcare institutions and distribution agreements with pharmaceutical wholesalers. This B2B model allows healthcare providers to purchase AM-01 through established channels, ensuring availability for patients suffering from treatment-resistant schizophrenia, thus supporting future growth in revenue driven by the product's therapeutic potential.Amani Therapeutics plans to use the recent Series A funding to enhance the clinical development of AM-01, which is aimed at addressing critical needs in neuropsychiatric care. The company is also looking to expand into international markets where treatment-resistant schizophrenia is prevalent, leveraging its collaborations to facilitate this growth. The funding will support ongoing research and development efforts, positioning AM-01 for a potential launch in key markets, enhancing accessibility to its innovative therapies.

## Funding rounds

- Series A, Mar 23, 2026, $25M — RTW Investments

## Investors

- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series A